Ascletis Pharma (HKG:1672) presented key preclinical results for ASC48, ASC30_48 fixed dose combination, and ASC37 at ObesityWeek 2026, a Monday bourse filing showed.
The two poster presentations feature in vitro activity and oral pharmacokinetics of ASC48; weight loss data for ASC30_48; and extended pharmacokinetics, in vitro insulin secretion activity, and weight-loss activity of ASC37.
ObesityWeek 2026 is being held in Washington, DC, from Nov. 14 to 17.